Want to see HK:2509 full AI Analyst Report?
Qyuns Therapeutics Co., Ltd. Class H (2509) AI Stock Analysis
Top Page
Qyuns Therapeutics Co., Ltd. Class H
(HKEX:2509)
The score is driven primarily by the sharp improvement in financial performance (strong margins and solid free cash flow) and a low P/E valuation. Offsetting these positives, technical indicators are neutral-to-weak with the price below key moving averages, and the recent profitability/cash flow turnaround is still relatively new given the prior multi-year loss history.
Qyuns Therapeutics Co., Ltd. Class H (2509) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 3.42B
- Dividend Yield
- ―
- Average Volume (3M)
- 132.70K
- Price to Earnings (P/E)
- 5.4
- Beta (1Y)
- 0.93
- Revenue Growth
- 230.35%
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 337
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Qyuns Therapeutics Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Qyuns Therapeutics Co., Ltd., a biotechnology company established in 2015 and headquartered in Taizhou, China, is focused on the discovery and clinical advancement of biologic therapies. Its primary mission is to address autoimmune and allergic disea...
Qyuns Therapeutics Co., Ltd. Class H Financial Statement Overview
Summary
Strong TTM inflection with revenue at 1.02B (+11.9%) and exceptionally high profitability (gross margin ~88.6%, operating margin ~53.9%, net margin ~53.3%). Cash generation is also robust (OCF 519.9M; FCF 515.9M) with strong conversion. Key risk is durability: results follow multiple years of losses (2021–2024), debt remains meaningful (686.5M), and the turnaround is relatively new.
Income Statement
82Very PositiveBalance Sheet
69PositiveCash Flow
85Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.02B | 786.08M | 158.79M | 14.75M | 9.66M | 21.35M |
| Gross Profit | 908.13M | 664.66M | 92.19M | -32.96M | 9.66M | -9.56M |
| EBITDA | 599.01M | 351.83M | -309.62M | -484.12M | -293.62M | -153.70M |
| Net Income | 546.10M | 306.31M | -335.57M | -507.75M | -298.19M | -411.04M |
Balance Sheet | ||||||
| Total Assets | 1.91B | 1.60B | 983.88M | 795.58M | 1.16B | 1.07B |
| Cash, Cash Equivalents and Short-Term Investments | 1.02B | 1.04B | 556.55M | 377.25M | 689.57M | 620.44M |
| Total Debt | 686.50M | 580.26M | 527.60M | 346.06M | 295.25M | 290.26M |
| Total Liabilities | 1.07B | 921.62M | 762.83M | 494.63M | 373.69M | 363.33M |
| Stockholders Equity | 861.02M | 694.33M | 228.98M | 294.76M | 641.72M | 670.35M |
Cash Flow | ||||||
| Free Cash Flow | 510.93M | 392.23M | -187.85M | -308.63M | -301.70M | -228.64M |
| Operating Cash Flow | 519.90M | 399.85M | -186.09M | -300.68M | -275.23M | -157.60M |
| Investing Cash Flow | -632.10M | 118.69M | -25.23M | 243.11M | -5.70M | -247.42M |
| Financing Cash Flow | -51.91M | 93.73M | 351.81M | 61.21M | 211.49M | 281.48M |
Qyuns Therapeutics Co., Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2509, the sentiment is Negative. The current price of 15.30 is below the 20-day moving average (MA) of 16.42, below the 50-day MA of 16.60, and below the 200-day MA of 17.55, indicating a bearish trend. The MACD of -0.32 indicates Positive momentum. The RSI at 35.37 is Neutral, neither overbought nor oversold. The STOCH value of 21.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2509.
Qyuns Therapeutics Co., Ltd. Class H Peers Comparison
Overall Rating
- HK:250974Outperform
HK:699870Outperform
HK:116748Neutral
HK:699645Neutral
HK:154144Neutral
HK:217139Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2509 | 74Outperform | HKD 3.47B | 5.36 | 70.24% | ― | 230.35% | ― |
| HK:6998 | 70Outperform | HKD 3.26B | 4.48 | 10.99% | ― | 1417.68% | 660.14% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1167 | 48Neutral | HKD 3.62B | 6.00 | 47.76% | ― | 286.20% | ― |
| HK:6996 | 45Neutral | HKD 1.80B | 29.59 | 6.51% | ― | 605.95% | ― |
| HK:1541 | 44Neutral | HKD 1.25B | -4.64 | -32.32% | ― | 28.93% | 27.27% |
| HK:2171 | 39Underperform | HKD 6.32B | -56.08 | -9.45% | ― | 68.12% | 81.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2509 | Qyuns Therapeutics Co., Ltd. Class H | 15.30 | -8.02 | -34.39% | |
| HK:6996 | Antengene Corporation Limited | 2.79 | -2.33 | -45.51% | |
| HK:6998 | Genor Biopharma Holdings Limited | 1.62 | -1.51 | -48.24% | |
| HK:1167 | Jacobio Pharmaceuticals Group Co., Ltd. | 4.60 | -2.66 | -36.64% | |
| HK:2171 | CARsgen Therapeutics Holdings Ltd. | 10.63 | -6.92 | -39.43% | |
| HK:1541 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H | 2.90 | -6.15 | -67.96% |
Qyuns Therapeutics Co., Ltd. Class H Corporate Events
Qyuns Therapeutics Swings to Interim Profit on Surging Licensing Revenue
Qyuns Therapeutics reported a sharp increase in unaudited interim revenue to RMB424.1 million for the six months ended June 30, 2026, driven mainly by RMB378.6 million in licensing income from overseas deals for QX027N and milestones for QX008N and Q...
Qyuns Therapeutics Sets Board Meeting to Approve 2026 Interim Results
Qyuns Therapeutics Co., Ltd. has scheduled a board meeting for August 19, 2026 to review and approve the group’s interim results for the six months ended June 30, 2026 and to authorize their publication. The meeting will also address other corp...
Qyuns Therapeutics Wins New QX027N Trial Approvals and Secures Global Licensing Deal
Qyuns Therapeutics announced that its long-acting bispecific antibody QX027N has received clinical trial approvals in China for chronic obstructive pulmonary disease and chronic rhinosinusitis with nasal polyps, adding two new respiratory indications...
Caldera-Synlogic Merger and $278 Million Raise Bolster Qyuns-Linked IBD Program
Caldera Therapeutics, Qyuns Therapeutics’ partner for the investigational IBD drug QX030N/CLD-423, has agreed to merge with Synlogic in an all-stock deal that will create a new holding company listed on the Nasdaq Capital Market under the ticke...
Qyuns Therapeutics to Fully Acquire Cellularforce in RMB86 Million Connected Deal
Qyuns Therapeutics has moved to fully consolidate its subsidiary Cellularforce by acquiring the remaining 34.0001% equity stake from Taizhou Huacheng for RMB86.02 million through its wholly owned unit Saifu Juli. The deal, priced via a public listing...
Qyuns Therapeutics Launches Share Buyback to Address Undervaluation Concerns
Qyuns Therapeutics Co., Ltd., a Hong Kong-listed Chinese biopharmaceutical company, develops therapeutic products within the healthcare and life sciences sector and is led by chairman and executive director Qiu Jiwan. The company aims to attract inve...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026